JPH 203-companion diagnostic agent-J-PharmaAlternative Names: JPH-211
Latest Information Update: 09 Mar 2015
At a glance
- Originator J-Pharma
- Class Diagnostic agents
- Mechanism of Action Amino acid transport system L inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 25 Feb 2015 Clinical trials in Solid tumours in Japan (unspecified route) (J-Pharma pipeline, February 2015)